Organo (6368) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2024, rose 8.9% year-over-year to ¥115,698 million, with operating profit up 39.1% to ¥19,746 million and profit attributable to owners of parent up 36.2% to ¥13,965 million.

• Orders received increased 8.3% year-over-year to ¥117,957 million, though the order backlog declined 7.0% to ¥116,472 million.

• The electronics industry drove growth, especially from semiconductor-related projects, while general industry and social infrastructure also contributed.

Financial highlights

• Gross profit for the nine months was ¥37,259 million, up from ¥29,790 million year-over-year.

• Basic earnings per share increased to ¥303.81 from ¥223.22 year-over-year.

• Total assets as of December 31, 2024, were ¥185,242 million, with net assets at ¥109,658 million and an equity-to-asset ratio of 59.1%.

• Comprehensive income rose 20.5% year-over-year to ¥13,813 million.

Outlook and guidance

• Full-year net sales forecast revised upward to ¥167,500 million, operating profit to ¥31,000 million, and profit attributable to owners of parent to ¥23,000 million.

• Basic earnings per share for the full year projected at ¥500.34.

• Orders received for the full year expected to be ¥155,000 million, below previous forecasts due to project timing shifts.

• Dividend forecast for the year raised to ¥142.00 per share.